BioNTech confirmed the successful completion of its public tender offer for CureVac on December 18, 2025, with the acceptance period closing at 0:01 Eastern Time. The all-stock transaction was valued ...
Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024 First participant dosed in seasonal flu Phase 2 study with ...
MUNICH (Reuters) - A German court on Tuesday invalidated a patent that was the basis of a patent violation lawsuit brought by CureVac against its domestic rival BioNTech, in a blow to CureVac's claims ...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on ...
CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market capitalization of $818.75 million, stands at a critical juncture in its ...
Acuitas said it collaborated with CureVac to develop vaccine technology CureVac accused of omitting Acuitas scientists from patent applications Nov 14 (Reuters) - Biotech company Acuitas Therapeutics ...
In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac's second-generation mRNA technology. This ...
A major regulatory milestone was achieved in November 2025 when Germany’s Federal Cartel Office (Bundeskartellamt) granted clearance for the takeover. BioNTech had initially announced the exchange ...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results